Navigation Links
European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane

MALVERN, Pa., Sept. 28 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that more than half of all European inpatients who receive anticoagulants during their hospital stay are administered Sanofi-Aventis's Clexane (marketed as Lovenox in the U.S. and France).

The new audit entitled The European Hospital Anticoagulant Market Guide is a comprehensive source for anticoagulant use in European hospitals. Released quarterly, the audit contains detailed clinical data from thousands of hospitalized patients receiving anticoagulants. Survey results are projected to the national level for France, Germany, Italy, Spain and the United Kingdom.

The audit also reveals that surgical venous thromboembolism (VTE) primary prophylaxis accounts for the largest share of inpatient anticoagulant use at 48 percent of all inpatients. However, non-surgical VTE and stroke prophylaxis remains a key area of growth opportunity for companies marketing and developing anticoagulant agents.

The European Hospital Anticoagulant Market Guide is designed to help biopharmaceutical companies quantify targeted patient segments, better understand treatment practices and customers, size commercial opportunity and formulate clinical development strategy.

Besides Clexane, Boehringer Ingelheim's Pradaxa, Bayer's Xarelto and all other anticoagulants used in European hospitals are tracked in this audit.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Arlington Medical Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
2. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
3. Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
4. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
5. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
6. European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years
7. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
8. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
9. Sunridge Schedules European Meetings
10. European Patent Office Upholds GlideScope® Video Laryngoscope Patent
11. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 F1000Workspace ... scientists - since it was launched just six months ago. ... management and authoring platform for scientists - since it was ... references have been loaded on to F1000Workspace - ... - since it was launched just six months ago. ...
(Date:11/24/2015)... , Nov. 24, 2015 iRhythm Technologies, Inc. , ... care, today announced that it will participate in the 27th Annual ... New York, NY . Kevin King ... Tuesday December 1, 2015 at 8:50am ET. ... . --> . --> ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . --> ... Diabetes Mellitus (T1DM), will be a key driver of market growth to ... The uptake of recently approved and pipeline premium products for Type ... to 2021, says GBI Research . ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) ... not meet the device regulations. , Come up short in an inspection and the ...
(Date:11/24/2015)... Richey, FL (PRWEB) , ... November 24, 2015 , ... ... deems a growing epidemic as deaths from prescription opioids in the United States grew ... and cocaine. In 2013 alone, opioids were involved in 37 percent of all fatal ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC launched ... Kickstarter last week and hit their goal of $20,000 in under 10 hours. ... aims to bring the new PRO Weight Loss Vest to the market. , The PRO ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... its exceptional customer service: the TrustDale certification. The award recognizes good companies for ... stone honing , tile and grout, and hard surface restoration company earned this ...
Breaking Medicine News(10 mins):